Skip to content
10-Q

Quarterly Report

RenovoRx, Inc. RNXT

0001641172-25-010935

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 36.57M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $14.58M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $7.15M
Current Liabilities Q1 2025 · Mar 31, 2025 $1.74M
Current Liabilities Q1 2025 · Dec 31, 2024 $1.91M
Total Liabilities Q1 2025 · Mar 31, 2025 $2.86M
Total Liabilities Q1 2025 · Dec 31, 2024 $3.64M
Current Assets Q1 2025 · Mar 31, 2025 $15.75M
Current Assets Q1 2025 · Dec 31, 2024 $7.83M
Total Assets Q1 2025 · Mar 31, 2025 $16.01M
Total Assets Q1 2025 · Dec 31, 2024 $8.12M
Shares Diluted Q1 2025 · Mar 31, 2024 14.95M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$2.2M
Stockholders Equity Q1 2025 · Mar 31, 2024 $1.77M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$3M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.07
Eps Basic Q1 2025 · Mar 31, 2024 −$0.07
Sga Expense Q1 2025 · Mar 31, 2024 $1.22M
Rd Expense Q1 2025 · Mar 31, 2024 $1.26M
Net Income Q1 2025 · Mar 31, 2024 −$1.08M
Operating Income Q1 2025 · Mar 31, 2024 −$2.48M